Cargando…

Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?

BACKGROUND: IGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown. METHODS: We evaluated muscle mass at L3 in patients enrolled in a randomized pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fogelman, David R., Holmes, Holly, Mohammed, Khalil, Katz, Matthew H. G., Prado, Carla M., Lieffers, Jessica, Garg, Naveen, Varadhachary, Gauri R., Shroff, Rachna, Overman, Michael J., Garrett, Christopher, Wolff, Robert A., Javle, Milind
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248412/ https://www.ncbi.nlm.nih.gov/pubmed/24740741 http://dx.doi.org/10.1007/s13539-014-0145-y

Ejemplares similares

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
por: Javle, Milind M, et al.
Publicado: (2010)

Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients
por: Mohindroo, Chirayu, et al.
Publicado: (2021)

Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer
por: Koay, Eugene J., et al.
Publicado: (2019)

Berberine promotes nerve regeneration through IGFR-mediated JNK-AKT signal pathway
por: Zhang, Hai-Na, et al.
Publicado: (2018)

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
por: Goldstein, Jennifer B., et al.
Publicado: (2017)

KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma
por: Murugesan, Navya, et al.
Publicado: (2021)

Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92‐Gene Assay
por: Raghav, Kanwal, et al.
Publicado: (2020)

Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma
por: Raghav, Kanwal, et al.
Publicado: (2021)

Blood exosomes regulate the tissue distribution of grapefruit-derived nanovector via CD36 and IGFR1 pathways
por: Wang, Qi-long, et al.
Publicado: (2018)

Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy
por: Crane, Christopher H., et al.
Publicado: (2009)

Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin
por: Ou, Da-Liang, et al.
Publicado: (2014)

Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait
por: Huey, Ryan W., et al.
Publicado: (2019)

Cancer of Unknown Primary Presenting as Bone‐Predominant or Lymph Node‐Only Disease: A Clinicopathologic Portrait
por: Huey, Ryan W., et al.
Publicado: (2021)

Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C(max) and improved tolerability, in patients with solid tumors
por: Ajani, Jaffer A., et al.
Publicado: (2020)

Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma
por: Overman, Michael J., et al.
Publicado: (2016)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Characterization, survival analysis, and expression of IGFR in tumor samples from patients diagnosed with Ewing family tumors treated at the Barretos Cancer Hospital()
por: Ferreira, Adriano Jander, et al.
Publicado: (2016)

Biglycan Regulates MG63 Osteosarcoma Cell Growth Through a LPR6/β-Catenin/IGFR-IR Signaling Axis
por: Aggelidakis, John, et al.
Publicado: (2018)

Glutamate Attenuates the Survival Property of IGFR through NR2B Containing N-Methyl-D-aspartate Receptors in Cortical Neurons
por: Zhao, Xia, et al.
Publicado: (2020)

ReishiMax inhibits mTORC1/2 by activating AMPK and inhibiting IGFR/PI3K/Rheb in tumor cells
por: Sohretoglu, Didem, et al.
Publicado: (2019)

Clinicopathological and Prognostic Significance of the EML4-ALK Translocation and IGFR1, TTF1, Napsin A Expression in Patients with Lung Adenocarcinoma
por: Bulutay, Pınar, et al.
Publicado: (2021)

Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes
por: Raghav, Kanwal, et al.
Publicado: (2016)

Reirradiation to the abdomen for gastrointestinal malignancies
por: Haque, Waqar, et al.
Publicado: (2009)

Limonin inhibits angiogenesis and metastasis of human breast cancer cells by suppressing the VEGFR2/IGFR1-mediated STAT3 signaling pathway
por: Chen, Jing, et al.
Publicado: (2020)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Alpinia oxyphylla Miq. fruit extract activates IGFR-PI3K/Akt signaling to induce Schwann cell proliferation and sciatic nerve regeneration
por: Chang, Yung-Ming, et al.
Publicado: (2017)

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
por: Churi, Chaitanya R., et al.
Publicado: (2014)

Updates in Gastrointestinal Oncology – insights from the 2008 44(th )annual meeting of the American Society of Clinical Oncology
por: Javle, Milind, et al.
Publicado: (2009)

Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology
por: Javle, Milind, et al.
Publicado: (2010)

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma
por: Chun, Yun Shin, et al.
Publicado: (2017)

Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction
por: Chouhan, Jay, et al.
Publicado: (2015)

PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer
por: Douglas, Julia E., et al.
Publicado: (2022)

A cathelicidin-related antimicrobial peptide suppresses cardiac hypertrophy induced by pressure overload by regulating IGFR1/PI3K/AKT and TLR9/AMPKα
por: Wang, Xiaofang, et al.
Publicado: (2020)

A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer
por: Katz, Matthew, et al.
Publicado: (2015)

Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma
por: Liu, Qingqing, et al.
Publicado: (2017)

Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling
por: Javle, Milind, et al.
Publicado: (2013)

The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer
por: Perri, Giampaolo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e4vn9pjfmq7evos2c01qhs71hn